Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004054 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 397
- Enrollment target
NCT00004054 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 397 participants.
The verdict
NCT00004054, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 397 participants
- Enrollment target
Study Summary
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus radiation therapy is more effective with or without combination chemotherapy for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy plus radiation therapy with or without combination chemotherapy in treating patients who have prostate cancer.
Interventions
- DRUG paclitaxel
- DRUG etoposide
- DRUG bicalutamide
- DRUG flutamide
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2000-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004054
The ClinicalTrials.gov registry entry for NCT00004054 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which paclitaxel is the first listed.
NCT00004054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004054 about?
NCT00004054 is a clinical study titled "Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer". RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividi...
What is the current status of trial NCT00004054?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 397 participants. The study started on 2000-01. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00004054?
The interventions under investigation include: paclitaxel (DRUG), etoposide (DRUG), bicalutamide (DRUG), flutamide (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00004054?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.